| Code | CSB-RA853495MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ESG-206, targeting TNFRSF13C, also known as BAFF receptor (BAFF-R). TNFRSF13C is a type III transmembrane protein exclusively expressed on B cells that serves as the primary receptor for B cell activating factor (BAFF). This receptor plays a critical role in B cell maturation, survival, and homeostasis by transducing signals essential for peripheral B cell development and immunoglobulin production. Dysregulation of BAFF-R signaling is implicated in various autoimmune disorders, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, as well as in B cell malignancies such as chronic lymphocytic leukemia and certain lymphomas.
ESG-206 represents a therapeutic antibody designed to modulate BAFF-R signaling pathways, making this biosimilar valuable for investigating B cell biology and immune regulation mechanisms. Researchers can utilize this antibody to explore BAFF-BAFF-R interactions, evaluate B cell depletion strategies, and study the molecular basis of autoimmune pathologies and B cell-related cancers in preclinical models.
There are currently no reviews for this product.